gene therapy sarepta - Search News

Order byBest matchMost fresh

Sarepta shares crash

Top News

Measures

Sarepta shares crash as second patient dies after receiving its gene therapy

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who had received its gene therapy, Elevidys, raising doubts on the safety and future demand for the treatment.

· 1d · on MSN

Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy

· 1d

Sarepta reports second patient death after treatment with Duchenne gene therapy

· 1d

Second patient death reported with gene therapy for muscular dystrophy

Sarepta reported the death over the weekend and provided additional details about its response, which includes pausing shipments of the therapy, Elevidys, for older patients who are no longer able to ...

· 1d

Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug

· 1d

Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK. Despite these developments,

STAT1d

After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other parents still push for the therapy.

1don MSN

Sarepta crashes after second death linked to Roche-partnered Elevidys

Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from acute liver failure in a patient treated with Elevidys, a gene therapy marketed with Roche ( OTCQX:RHHBY) for Duchenne muscular dystrophy (DMD), a rare muscle disorder.